If you spend any time online right now, you've probably heard people talking about peptides. Weight loss, healing, muscle recovery, better sleep, slower aging — the claims are everywhere, and so are the before-and-after photos.

I get why people are curious. Some peptide-based medications genuinely are important medical breakthroughs. But as a pharmacist, I think patients deserve a more honest conversation than what most of the internet is offering. So, here's mine.

First — what even is a peptide?

Peptides are short chains of amino acids, which are the building blocks of proteins. Your body already makes and uses many of them. Some act like hormones or signaling molecules that regulate appetite, blood sugar, tissue repair, and other functions.

The most talked-about peptide medications right now are GLP-1 drugs like semaglutide and tirzepatide — Ozempic, Wegovy, Zepbound. These went through the full FDA approval process: large clinical trials, rigorous safety reviews, manufacturing standards, the whole thing. That process matters, and it's part of why we can talk about those drugs with confidence.

Not every peptide has that story behind it.

The evidence gap is real

One of the biggest problems with how peptides get discussed online is that all of them get lumped together as if they share the same level of scientific backing. They don't.

Take BPC-157, which has a huge following in wellness and recovery communities. People swear by it for gut health, healing, inflammation. But the human trial data is thin. Most of what's out there is animal research, small early-stage studies, and a whole lot of anecdotes. That doesn't mean it's worthless — it means the science hasn't caught up to the enthusiasm yet. Those are very different things.

"Promising" and "proven" aren't the same, and in medicine, that gap matters.

The sourcing problem is where I lose sleep

Here's the part that concerns me most. A significant amount of peptide products are being sold online under labels like "research use only" or "not for human consumption" — legal workarounds that let sellers move products without the regulatory oversight that actual medications require.

The FDA has specifically warned about vendors marketing these for human use while hiding behind research-product language. The risks are real: contamination, mislabeled concentrations, poor sterility, sketchy refrigeration during shipping. For anything injectable, sterility isn't a small detail. It's the whole ballgame.

The dosing issue is also serious. The FDA has documented hospitalizations tied to compounded semaglutide where patients accidentally took five to ten times the intended dose — often because of confusion between units, syringes, and concentrations. That's not a minor miscommunication.

So where does that leave us?

Somewhere in the middle, honestly. Peptide medicine has real potential, and I think we'll eventually see meaningful breakthroughs — in metabolic disease, inflammation, recovery, maybe more. Some of that work is already happening.

But right now, for a lot of these compounds, the internet is moving faster than the science. My advice: be skeptical of online sellers, ask hard questions about where products are made and tested, work with a licensed provider, and take dramatic testimonials with a heavy dose of salt.

Excitement about what might be true isn't the same as evidence for what is true. That's not cynicism — that's just how good science works.